Metolazone

Indications and usage: Metolazone tablets, USP, are indicated for the treatment of salt and water retention including: · edema accompanying congestive heart failure; · edema accompanying renal diseases, including the nephrotic syndrome and states of diminished renal function. Metolazone tablets, USP, are also indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class. MYKROX Tablets, a more rapidly available form of metolazone, are intended for the treatment of new patients with mild to moderate hypertension.

CLINICAL PHARMACOLOGY Metolazone is a quinazoline diuretic, with properties generally similar to the thiazide diuretics. The actions of metolazone result from interference with the renal tubular mechanism of electrolyte reabsorption. Metolazone acts primarily to inhibit sodium reabsorption at the cortical diluting site and to a lesser extent in the proximal convoluted tubule. Sodium and chloride ions are excreted in approximately equivalent amounts. The increased delivery of sodium to the distal tubular exchange site results in increased potassium excretion. Metolazone does not inhibit carbonic anhydrase.

Pharmacokinetic profiling of Metolazone demonstrates an elimination half-life of Steady-state plasma equilibrium reached over 6–10 hour t½ intervals for Metolazone with Approximately 51% to 63% enteral uptake across labeled Metolazone strengths systemic bioavailability; clearance proceeds via predominantly hepatic biotransformation with renal elimination of polar metolazone conjugates, reaching clinical onset within maximum serum exposure occurs 2–4 hours after metolazone dosing.

Titration schedules for Metolazone (10 mg/1 Tablet → 5 mg/1 Tablet → 2.5 mg/1 Tablet → 10mg Tablet → 2.5mg Tablet) require excluding contraindications anuria, hepatic coma or precoma, known allergy or hypersensitivity to metolazone.; confirmed ige-mediated allergy or cutaneous reaction to metolazone (metolazone) components; real-world patient logs highlight headache (6.8% of reports), dizziness (6.7% of reports), fatigue (6.1% of reports) alongside a 80.00% Worth-It consensus.